Bacteria and bacterial derivatives as drug carriers for cancer therapy

J Control Release. 2020 Oct 10:326:396-407. doi: 10.1016/j.jconrel.2020.07.009. Epub 2020 Jul 16.

Abstract

The application of bacteria and bacteria-derived membrane vesicles (MVs) has promising potential to make a great impact on the development of controllable targeted drug delivery for combatting cancer. Comparing to most other traditional drug delivery systems, bacteria and their MVs have unique capabilities as drug carriers for cancer treatment. They can overcome physical barriers to target and accumulate in tumor tissues and initiate antitumor immune responses. Furtherly, they are able to be modified both genetically and chemically, to produce and transport anticancer agents into tumor tissues with improved safety and efficacy of cancer treatment but decreased cytotoxic effects to normal cells. In this review, we present some examples of tumor-targeting bacteria and bacteria-derived MVs for the delivery of anticancer drugs, including chemo-therapeutic, radio-therapeutic, photothermal-therapeutic, and immuno-therapeutic agents. We also discuss the advantages as well as the limitations of these tumor-targeting bacteria and their MVs used as platforms for controlled delivery of anticancer therapeutic agents, and further highlight their great potential on clinical translation.

Keywords: Bacteria; Bacteria-derived membrane vesicles; Cancer; Drug delivery; Immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Bacteria
  • Drug Carriers / therapeutic use
  • Drug Delivery Systems
  • Humans
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents
  • Drug Carriers